Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Linn

Showing results (161-170 of 467) with videos related to

Pageof 47
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumorsG Giaccone, S C Linn, J Welink, et al.
International Journal of Cancer|September 7, 2019
IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancerDinja T Kruger, Xanthippi Alexi, Mark Opdam, et al.
Biochemistry|August 13, 2010
Stereoselective hydrolysis of organophosphate nerve agents by the bacterial phosphotriesterasePing-Chuan Tsai, Andrew Bigley, Yingchun Li, et al.
Annals of Surgical Oncology|January 23, 2010
Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signatureStella Mook, Michael Knauer, Jolien M Bueno-de-Mesquita, et al.
Cancer Informatics|June 28, 2016
The Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer CareElisabeth van der Meijde, Alfons J M van den Eertwegh, Sabine C Linn, et al.
Bone Marrow Transplantation|April 12, 2011
Single center retrospective analysis of BU-based conditioning regimens in allogeneic transplantationA M Wong, J C Allen, Y T Goh, et al.
The Breast Journal|May 21, 2013
Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancerGabe S Sonke, Ingrid A Mandjes, Marjo J Holtkamp, et al.
Journal of the National Cancer Institute|June 8, 2021
Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer PatientsGwen M H E Dackus, Katarzyna Jóźwiak, Gabe S Sonke, et al.
Breast Cancer Research and Treatment|October 28, 2020
Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancerGwen M H E Dackus, Katarzyna Jóźwiak, Elsken van der Wall, et al.
European Journal of Cancer (Oxford, England : 1990)|December 25, 2017
Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort studyG M H E Dackus, K Jóźwiak, G S Sonke, et al.
Pageof 47

Showing results (161-170 of 467) with videos related to

Sort By:
Pageof 47
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumorsG Giaccone, S C Linn, J Welink, et al.
International Journal of Cancer|September 7, 2019
IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancerDinja T Kruger, Xanthippi Alexi, Mark Opdam, et al.
Biochemistry|August 13, 2010
Stereoselective hydrolysis of organophosphate nerve agents by the bacterial phosphotriesterasePing-Chuan Tsai, Andrew Bigley, Yingchun Li, et al.
Annals of Surgical Oncology|January 23, 2010
Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signatureStella Mook, Michael Knauer, Jolien M Bueno-de-Mesquita, et al.
Cancer Informatics|June 28, 2016
The Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer CareElisabeth van der Meijde, Alfons J M van den Eertwegh, Sabine C Linn, et al.
Bone Marrow Transplantation|April 12, 2011
Single center retrospective analysis of BU-based conditioning regimens in allogeneic transplantationA M Wong, J C Allen, Y T Goh, et al.
The Breast Journal|May 21, 2013
Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancerGabe S Sonke, Ingrid A Mandjes, Marjo J Holtkamp, et al.
Journal of the National Cancer Institute|June 8, 2021
Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer PatientsGwen M H E Dackus, Katarzyna Jóźwiak, Gabe S Sonke, et al.
Breast Cancer Research and Treatment|October 28, 2020
Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancerGwen M H E Dackus, Katarzyna Jóźwiak, Elsken van der Wall, et al.
European Journal of Cancer (Oxford, England : 1990)|December 25, 2017
Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort studyG M H E Dackus, K Jóźwiak, G S Sonke, et al.
Pageof 47